life scienc diagnost tool
weaker india mass spec caus top-lin miss
trim pt maintain buy constant
currenc revenu growth fell short guidanc msd growth driven
unexpectedli weaker perform india mass spectrometri
ms busi ep beat larg attribut better forecast
tax rate full year constant currenc revenu guidanc reiter
howev base order visibl ep guidanc rais reflect
beat favor fx impact unexpect result make
us increment cautiou india outlook sale
well water divis sale face non-pharma segment particularli
industri also note inher lumpi ms instrument sale
histor compani key long-term growth driver remain
bright spot specif growth pharma/biotech
segment exclud india china growth prior
year recur revenu despit fewer calendar day
furthermor wat increas flexibl capit deploy capac
recent tax reform increment billion share repurchas
author next three year plu million remain
pre-exist program combin wat continu oper
disciplin despit industry-lead margin could provid upsid
ep estim beyond lower pt reflect
modestli reduc near-term end market visibl
constant currenc revenu growth estim trim bp well
sector-wid multipl compress ytd remain bullish
lt growth potenti stronger capit posit
model updat revis revenu ep estim
y/i y/i vs
previous revis revenu ep
estim y/i y/i vs
previous
valuat pt base price-to-earnings
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exhibit varianc million except per share data
exhibit segment detail growth constant currenc
particular strength core lc lc-m
sold pharma custom
full year
driven ms weak solid
full year
full year
actualguidancestreet estimate btig chang gross incom oper margin rate incom chang
exhibit end market color growth constant currenc
 growth broad-bas
pick spend mid-siz larg
pharma custom cautiou earlier
year
broad-bas growth across region pharma
medic research custom
strength ta instrument
solid growth pharma
weak biomed research market
industri academic/govern drag
region
strength small molecul applic
pharma demand remain robust saw strength
continu strong demand biopharma applic
strong servic revenu larg grow
instal base system
china grew strong comparison
across key end market china grew
full year
india rebound disrupt due
new gst system implement india grew hsd
steadi growth japan full year
china sale
weak india
japan lsd in-lin compani
strong demand doubl digit growth
exclud india sale doubl digit
china solid rebound india
growth china msd develop market
tough comparison prior year
declin notabl mass spec sale chemic
broad-bas perform across major
food environment custom due part
territori realign
ta continu strong momentum seen last year
grew
industri china bit lumpi
strong growth china driven food research
strong spend academ custom focus
weak biomed research custom
biomed omic research
continu stabl demand
continu global growth
pharma industri end market
demand pharma end market
consist growth recur revenu
y/i growth industri market
consist growth recur
consist prior year
growth rate sale growth rate
reduct y/i due increas
flexibl deploy wat cash
balanc result tax reform
posit impact lower tax
rate approxim
impact due intang base
broaden provis lower tax
benefit stock compens
result tax rate reduct
continu share repurchas
program approxim
compar benefit
 tax rate reduct tax
approxim million share
moder increas expens
neutral impact fx
fx benefit
fiscal year end dec million except per share profit develop intang incom expens oper incom incom incom analysiscost margin gener administr develop margin tax margin growthnet margin bpsoper incom margin bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
